reports
- Ahmed Ben Salem
FP TOTAL SE
AC ACCOR SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
EQNR EQUINOR ASA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
AAL ANGLO AMERICAN PLC
SU SCHNEIDER ELECTRIC SE
BNP BNP PARIBAS SA CLASS A
SK SEB SA
GFC GECINA SA
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SAF SAFRAN S.A.
AIR AIRBUS SE
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
SKF B SKF AB CLASS B
INX IMCD N.V.
CLNX CELLNEX TELECOM S.A.
STM STMICROELECTRONICS NV
UMI UMICORE
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
ADYEN ADYEN NV
DSY DASSAULT SYSTEMES SA
SGSN SGS SA
TEN TENARIS S.A.
- Ahmed Ben Salem
FP TOTAL SE
AC ACCOR SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
EQNR EQUINOR ASA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
AAL ANGLO AMERICAN PLC
SU SCHNEIDER ELECTRIC SE
BNP BNP PARIBAS SA CLASS A
SK SEB SA
GFC GECINA SA
RMS HERMES INTERNATIONAL SCA
RCO REMY COINTREAU SA
SAF SAFRAN S.A.
AIR AIRBUS SE
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
SKF B SKF AB CLASS B
INX IMCD N.V.
CLNX CELLNEX TELECOM S.A.
STM STMICROELECTRONICS NV
UMI UMICORE
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
ADYEN ADYEN NV
DSY DASSAULT SYSTEMES SA
SGSN SGS SA
TEN TENARIS S.A.
- Martijn Den Drijver
Umicore : Cautious tone Battery Materials but 2024 EBITDA guidance mai...
>Reiterating 2024 EBITDA guidance of €900-€950m - Umicore has published a 1 page qualitative trading update about Q1 2024 in which it reiterated EBITDA guidance for 2024 (€900-€950m) so in that sense there are little surprises. Consensus is at €932m and we are at €909m. No analyst call is planned.Catalysis and Recycling performing in line with expectations - Umicore states that Catalysis is making headway on costs and efficiency gains (also in WC) whi...
- ING Helpdesk
Benelux Morning Notes
Basic-Fit: 1Q24 update in line, FY24 outlook in line with consensus at mid-point. bpost: Agreement on Flemish newspaper delivery; risk of provisions largely removed. Cofinimmo: Q1 results in line. Corbion: Tail wags the dog. IMCD: The last hurdle was a harsh clip. Proximus: Strong start to the year, guidance unchanged ahead of Digi arrival. Recticel: Kingspan 1Q24 trading update. Signify: 1Q24 results; revenue decline accelerates. Umicore: Confirms FY 2024 EBITDA guidance range. ...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Umicore FIRST LOOK: No surprises in 1Q performance, FY guidance mainta...
Umicore commented that market dynamics in 1Q were in line with its expectations and the company reiterated its FY24 adj EBITDA guidance range of € 900-950m which represents at midpoint a 5% drop y/y. We continue to believe Umicore is well placed to play an important role in the electrification of transportation as we believe that global OEMs are still determined to establish local supply chains in Europe and North America. HLM and solid-state technologies will in our opinion support the position...
- Frank Claassen
Umicore - On track in another transition year
• In its qualitative Q1-24 trading update Umicore indicated that so far market dynamics are in line with its expectations. It confirms its FY24 EBITDA guidance range of EUR 900-950m.• We stick to our view that the doubts on battery materials are unlikely to be removed soon and that 2024 will be another transition year.• We stick to Hold and TP of EUR 23 based on our SOTP with an overall target EV/EBITDA of around 8x.
Umicore S.A.: 1 director
A director at Umicore S.A. bought 4,930 shares at 20.290EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Ageas and BNP Paribas: Transparency notification
Ageas and BNP Paribas: Transparency notification Ageas and BNP Paribas: Transparency notification In accordance with the rules on financial transparency*, BNP Paribas has notified Ageas on 22 April 2024 that, on 19 April 2024, its interest has exceeded the legal threshold of 5% of the shares issued by Ageas. Its current shareholding stands at 6.65%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Notification byA parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a D...
Ageas and Fosun: Transparency notification
Ageas and Fosun: Transparency notification Ageas and Fosun: Transparency notification In accordance with the rules on financial transparency*, Fosun has notified Ageas on 22 April 2024 that, on 19 April 2024, its interest has fallen below the legal threshold of 5% of the shares issued by Ageas. Its current shareholding stands at 4.64%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Notification byA parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a. Date on which the threshold is crossed19 Apr...
Ageas et Fosun: Notification de transparence
Ageas et Fosun: Notification de transparence Ageas et Fosun: Notification de transparence Conformément aux règles de transparence financière*, Fosun a introduit le 22 avril 2024 une notification annonçant que, le 19 avril 2024, sa participation a franchi, à la baisse, le seuil légal de 5% des actions émises par Ageas et atteint 4,64%. Motif de la notificationAcquisition ou cession de titres conférant le droit de vote ou de droits de vote Notification parUne entreprise mère ou une personne détenant le controle Personne(s) tenue(s) à notificationVoir annexe 1a. Date de dépassement du seu...
Ageas en Fosun: Transparantiekennisgeving
Ageas en Fosun: Transparantiekennisgeving Ageas en Fosun: Transparantiekennisgeving Fosun informeerde Ageas op 22 april 2024, overeenkomstig de financiële transparantievereisten*, dat zijn belang op 19 april 2024 onder de wettelijke drempel van 5% van de door Ageas uitgegeven aandelen is gedaald en nu 4,64% bedraagt. Reden van de kennisgevingVerwerving of overdracht van stemrechtverlenende effecten of stemrechten Kennisgeving doorEen moederonderneming of een controlerende persoon Kennisgevingsplichtige perso(o)n(en)Zie bijlage 1a. Datum van drempeloverschrijding19 april 2024 Overschre...
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: Additional CIDP data at AAN
argenx announced additional detail on its Phase 3 ADHERE data with Vyvgart Hytrulo, showcasing its speed of onset and depth of response. We believe that Vyvgart Hytrulo is well positioned vs. the approved standard-of-care IVIg/SCIg across patient types, and look forward to the FDA decision (PDUFA: June 21, 2024). € 435 TP and Buy rating reiterated.
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive ...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
- David Seynnaeve
- PhD
argenx - New CIDP & gMG data further underlines VYVGART (Hytrulo)'s va...
• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG init...
- Carole Braudeau
- Carole Braudeau
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.